title: Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
abstract: This phase 3 study evaluated quality of life, functioning, and productivity after treatment with extended-release (ER) hydrocodone formulated with CIMA®Abuse-Deterrence Technology platform.
  
  
  
  Patients with chronic pain were rolled over from a 12-week placebo-controlled hydrocodone ER study or were newly enrolled. Hydrocodone ER doses were titrated (15 to 90 mg every 12 hours) to an analgesic dose, and patients received up to 52 weeks of open-label treatment. Assessments included Clinician Assessment of Patient Function (CAPF), Patient Assessment of Function (PAF), Brief Pain Inventory-Short Form (BPI-SF), 36-item Short-Form Health Survey (SF-36), Sheehan Disability Scale (SDS), and World Health Organization Health and Work Performance Questionnaire-Short Form (HPQ-SF).
  
  
  
  Of 330 enrolled patients, 291 composed the full analysis population. By week 4, ≥ 50% of patients showed improvement from baseline in all 5 CAPF domains (general activities, walking, work/daily living, relationships, and enjoyment of life) and 6 of 7 PAF domains (work attendance, work performance, walking, exercise, socializing, and enjoying life). Mean decreases from baseline of 2 to 3 points were noted for BPI-SF pain interference questions from week 4 through endpoint. Mean improvements from baseline to endpoint in SF-36 subscales ranged from 3.3 to 22.3, and SDS scores improved from moderate (4.8 to 5.1) to mild (2.5 to 2.8) disruptions in work/school, social life, and family life. At endpoint, mean HPQ-SF absolute absenteeism scores decreased from 13.6 to 10.0 hours lost/month and absolute presenteeism scores improved from 67.0 to 77.1.
  
  
  
  Patients receiving hydrocodone ER showed early numeric improvements in functioning that continued throughout this 12-month study.
authors: Gold Coast Research, LLC, Plantation, Florida, U.S.A.
authors: Martin E
authors: ME
authors: Hale
authors: Teva Pharmaceuticals, Frazer, Pennsylvania, U.S.A.
authors: Thomas R
authors: TR
authors: Zimmerman
authors: Teva Pharmaceuticals, Frazer, Pennsylvania, U.S.A.
authors: Yuju
authors: Y
authors: Ma
authors: Teva Pharmaceuticals, Frazer, Pennsylvania, U.S.A.
authors: Richard
authors: R
authors: Malamut
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy* / Q000523:psychology; D003692:Delayed-Action Preparations; D004185:Disability Evaluation; D004339:Drug Compounding; D004522:Educational Status; D004526:Efficiency; D005260:Female; D006801:Humans; D006853:Hydrocodone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000517:prevention & control*; D010147:Pain Measurement; D011788:Quality of Life; D012919:Social Behavior; D013607:Tablets; D014937:Work; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D013607:Tablets; D006853:Hydrocodone
keywords: chronic pain; extended-release; hydrocodone; opioid analgesics; productivity; quality of life